NYSE · AMGN
Healthcare · Drug Manufacturers - General
$375.65
Down-$5.85 (-1.53%)
Updated Sep 16, 2026, 10:50 AM
SID Score
6.5/10
Composite research score
Smart Money
51/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AMGN closed at $375.65 after 20 trading sessions, down 11.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $380.23 | $381.04 | $375.15 | $375.65 | 2.61M |
| Sep 14, 2026 | $381.94 | $384.61 | $376.76 | $381.50 | 2.71M |
| Sep 11, 2026 | $386.135 | $386.99 | $377.22 | $377.35 | 2.27M |
| Sep 10, 2026 | $387.84 | $391.666 | $381.51 | $382.47 | 3.43M |
| Sep 9, 2026 | $393.065 | $395.55 | $389.28 | $391.27 | 2.92M |
| Sep 8, 2026 | $408.90 | $410.025 | $391.17 | $393.17 | 6.83M |
| Sep 4, 2026 | $437.03 | $441.85 | $435.00 | $437.23 | 1.66M |
| Sep 3, 2026 | $445.67 | $445.815 | $438.0801 | $444.12 | 1.84M |
| Sep 2, 2026 | $440.65 | $445.57 | $435.00 | $442.84 | 2.29M |
| Sep 1, 2026 | $435.301 | $438.65 | $431.00 | $438.12 | 2.36M |
| Aug 31, 2026 | $428.59 | $431.85 | $426.00 | $429.88 | 2.34M |
| Aug 28, 2026 | $437.89 | $437.89 | $430.72 | $432.42 | 1.74M |
| Aug 27, 2026 | $433.08 | $442.13 | $431.01 | $436.99 | 1.76M |
| Aug 26, 2026 | $441.00 | $442.885 | $438.24 | $440.34 | 2.29M |
| Aug 25, 2026 | $443.26 | $447.03 | $441.26 | $442.24 | 2.1M |
| Aug 24, 2026 | $440.31 | $445.87 | $435.51 | $443.84 | 2.46M |
| Aug 21, 2026 | $431.72 | $440.51 | $429.38 | $439.33 | 2.11M |
| Aug 20, 2026 | $435.78 | $441.34 | $431.07 | $433.73 | 2.91M |
| Aug 19, 2026 | $430.24 | $443.20 | $429.38 | $442.36 | 2.54M |
| Aug 18, 2026 | $421.64 | $427.39 | $420.72 | $425.28 | 2.59M |
The latest Smart Investors Daily articles mentioning AMGN.
AMGN research
Company profile and research snapshot.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HSBC | Hold | — |
| Sep 8, 2026 | BMO Capital | Market Perform | — |
| Sep 8, 2026 | Cantor Fitzgerald | Neutral | — |
| Sep 4, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 20, 2026 | Piper Sandler | Overweight | — |
Generated Sep 15, 2026, 9:01 PM
Amgen shares declined 1.53% today amid a broader market sentiment shift toward defensive positioning as consumer confidence weakens and the Fed signals potential rate hikes ahead. While the company continues to generate operational momentum with regulatory wins and strategic technology implementations, macro headwinds are weighing on biotech valuations more broadly.
Bottom line: Amgen's modest 1.53% decline appears driven by macro market concerns rather than company-specific negative developments, with the IMDELLTRA® approval actually representing a positive catalyst. Investors should view this pullback as a potential entry point for a defensive healthcare position, though broader Fed policy risks and competitive pressures warrant continued monitoring.
SeekingAlpha · Sep 15, 2026
Amgen Inc. (AMGN) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsThomas J.
Yahoo · Sep 15, 2026
ADM, COCO, AMGN and CNC offer defensive exposure as inflation, oil prices and weak consumer sentiment fuel market volatility.
Yahoo · Sep 15, 2026
Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.
Yahoo · Sep 14, 2026
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Interpretive context generated from the platform’s current data sources.
Amgen Inc. shares closed at $381.50, reflecting a single-session decline of approximately 2.50%, per SID market data. Over the trailing one-month period, the stock has retreated 9.33%, though it maintains a positive three-month return of 6.58% and a robust one-year gain of 19.65%. The stock is currently trading below its 50-day moving average of $399.10 but remains above its 200-day moving average of $366.19, according to Massive/Polygon technical data. Notably, the 14-day relative strength index has fallen to 18.8, placing Amgen deeply in oversold territory and indicating significant near-term selling pressure. The company's beta of 0.472 reflects substantially lower volatility relative to the broader market, consistent with its defensive Healthcare sector positioning. Average daily trading volume stands at approximately 2.89 million shares, supporting a total market capitalization of roughly $209.2 billion.
Amgen Inc. currently trades at a price-to-earnings ratio of 27.13, per SID market data, positioning the biotechnology giant at a moderate premium relative to the broader Healthcare sector. The company's PEG ratio stands at 2.72, according to SEC filings and consensus growth estimates, suggesting the current earnings multiple exceeds the expected growth rate on a relative basis. Amgen's price-to-book ratio registers at 24.16, a level reflective of the company's significant intangible asset base, including its extensive biologics portfolio and intellectual property. The dividend yield of approximately 2.49% provides a meaningful income component for shareholders, notably above the S&P 500 average. With a market capitalization of $209.2 billion, Amgen remains one of the largest independent biotechnology companies globally. The valuation profile reflects the market's pricing of Amgen's established revenue streams alongside its pipeline development trajectory.
Amgen Inc. registers a composite smart money score of 51 out of 100, reflecting a neutral overall signal, per SID market data. Institutional ownership conviction scores a perfect 25 out of 25, indicating robust positioning among major fund managers and pension funds as documented in 13F institutional filings. Insider activity shows a score of 8.6 out of 25, with SEC Form 4 filings revealing 15 insider transactions over the past 90 days, comprising 9 purchases and 6 sales. The net insider buying trend suggests mild confidence among corporate executives and directors. Dark pool activity registers at 10.5 out of 25, indicating moderate levels of off-exchange institutional block trading. Congressional trading activity scores 6.8 out of 25, reflecting limited disclosed legislative branch transactions in the stock. The divergence between strong institutional conviction and more muted insider and dark pool signals contributes to the overall neutral composite reading, suggesting no decisive directional bias from sophisticated market participants.
Amgen Inc. has demonstrated a consistent pattern of earnings outperformance across its three most recently reported quarters, according to company earnings reports. In the most recent quarter reported on August 4, 2026, Amgen posted earnings per share of $6.29, exceeding the consensus analyst estimate of $5.60 by $0.69, representing a 12.3% positive surprise. The prior quarter, reported April 30, 2026, showed EPS of $5.15 against estimates of $4.76, a $0.39 beat. The February 3, 2026 quarter delivered $5.29 in EPS versus the $4.75 estimate, a $0.54 upside surprise. Looking ahead, analyst estimates project EPS of $4.81 for the upcoming quarter with results expected February 2, 2026. The trailing three-quarter average surprise of $0.54 per share underscores Amgen's operational execution and the tendency for consensus estimates to understate the company's earnings power.
Wall Street sentiment toward Amgen Inc. has shifted notably in recent weeks, with two prominent firms downgrading their recommendations in September 2026, per Wall Street analyst reports. HSBC downgraded the stock from Buy to Hold on September 10, while BMO Capital lowered its rating from Outperform to Market Perform on September 8. On the same date, Cantor Fitzgerald reiterated its Neutral stance. Wells Fargo maintained its Equal-Weight rating on September 4, and Piper Sandler maintained its Overweight rating on August 20, according to SID consensus data. The clustering of downgrades and neutral reiterations reflects a growing cautious posture among sell-side analysts, coinciding with the stock's recent pullback below its 50-day moving average. Piper Sandler's Overweight rating stands as the sole bullish call among the five most recent actions. The prevailing shift toward hold-equivalent ratings suggests analysts see limited near-term catalysts following the recent earnings beat cycle.
The latest Smart Investors Daily articles mentioning AMGN.
